Pharmaceutical composition comprising enavogliflozin and metformin
Patent Information
- Application Number
- MYPI2025003929
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-30
- Filing Date
- 2023-12-28
- Publication Date
- 2024-06-30
AI Technical Summary
Formulating a combination pharmaceutical composition of metformin and inavogliflozin is challenging due to their significant content difference, leading to difficulties in uniform mixing and sustained release, particularly because inavogliflozin's low content requires immediate release while metformin's high water solubility necessitates a sustained-release formulation, complicating the creation of a single matrix tablet.
A compartmentalized formulation where inavogliflozin and metformin are formulated separately as distinct compartments within a single dosage form, with inavogliflozin comprising 10 to 20 parts and metformin comprising 80 to 90 parts by weight, using specific excipients and disintegrants to ensure appropriate dissolution rates and bioavailability.
This approach allows for the successful creation of a bilayer tablet that maintains the medicinal efficacy of both metformin and inavogliflozin, achieving desired dissolution profiles and bioavailability, overcoming the challenges of content differences and release mechanisms.
Smart Images

Figure PI2025003929_DRAWING_001 
Figure PI2025003929_DRAWING_002
Abstract
Description
Pharmaceutical composition comprising inabogliflozin and metformin
[0001] The present invention relates to a pharmaceutical composition comprising inabogliflozin and metformin.
[0002] Metformin, an oral biguanide hypoglycemic agent, is widely used as a first-line treatment for diabetes. Metformin has a blood sugar-lowering effect. One known mechanism of action is to activate AMP-activated protein kinase (AMPK) in the liver, thereby inhibiting gluconeogenesis, promoting cellular glucose uptake, and suppressing metabolic syndrome.
[0003] Metformin has excellent glycated hemoglobin (HbA1c)-enhancing effects, is less likely to cause adverse effects such as weight gain or hypoglycemia, and significantly reduces both diabetes-related and total mortality. However, it can cause gastrointestinal side effects such as diarrhea, abdominal discomfort, nausea, and vomiting, and caution is advised when administering it to patients with severe renal or hepatic impairment.
[0004] Because metformin alone often fails to control blood sugar levels, sulfonylureas have been commonly prescribed as second-line diabetes treatments. However, long-term administration of insulin secretagogues like sulfonylureas can cause a decrease in pancreatic beta cells, ultimately leading to decreased insulin secretion.
[0005] In addition, oral diabetes treatments such as α-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 receptor inhibitors are also used in combination with metformin.
[0006] Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of antihyperglycemic agents. SGLT2 inhibitors decrease glucose reabsorption in the proximal nephron, thereby increasing glucose excretion through an insulin-independent mechanism. The safety and efficacy of SGLT2 inhibitors for the treatment of type 2 diabetes have been confirmed in numerous studies.
[0007] The currently approved SGLT-2 inhibitors include dapagliflozin, empagliflozin, ipragliflozin, ertugliflozin, and enavogliflozin.
[0008] Inabogliflozin (compound name: (2S,3R,4R,5S,6R)-2-(7-chloro-6(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol) is a drug disclosed in U.S. Patent Publication No. 2015 / 0152075, and has been reported to exhibit excellent blood sugar lowering effects at a dosage of 0.3 mg, which is less than one-thirtieth of the existing SGLT2 inhibitors.
[0009] Metformin can be administered in doses of up to 2000 mg per day, and tablets with single doses of 500 mg, 750 mg, and 1000 mg have been developed.
[0010] Combination therapy with metformin and SGLT2 inhibitors has been developed, including combination compositions of metformin and dapagliflozin and combination compositions of metformin and empagliflozin. Based on a 1,000 mg dose of metformin, the dapagliflozin content is approximately 10 mg, and the empagliflozin content is approximately 12.5 mg.
[0011] However, in the case of inabogliflozin, the single dose is 0.3 mg, which is less than about 1 / 30 of the dose of existing SGLT2 inhibitors, so it is difficult to implement as a combination preparation, unlike combination preparations with metformin and existing SGLT2 inhibitors.
[0012] While metformin contains 500 to 1000 mg per tablet, inavogliflozin contains 0.3 mg per tablet. Therefore, the difference in the active ingredient contents is so large that it is very difficult to mix them evenly when formulated into a single matrix tablet using a conventional formulation method. In addition, metformin is a drug that is highly soluble in water, and when formulated into a conventional tablet, rapid drug release can cause excessive hypoglycemia and gastrointestinal disorders. Therefore, it is necessary to develop a sustained-release formulation that releases slowly. In this case, there is a major problem that the release of inavogliflozin, which should be released immediately, can be delayed due to the high viscosity, swelling sustained-release agent used for the sustained release of metformin. Therefore, it is difficult to expect that metformin and inavogliflozin will be formulated into a single matrix tablet.
[0013] We can consider the case of Astrazeneca's Zigduo tablet, a combination drug of dapagliflozin and metformin, which was formulated as a bilayer tablet. However, when compared to the highest dose of Zigduo tablet, which is 10 mg of dapagliflozin and 1000 mg of metformin, the difference in content between the two ingredients in the dose of 0.3 mg of inavogliflozin and 1000 mg of metformin is so great that it is not easy to formulate these drugs as a bilayer tablet.
[0014] The total weight of the pharmaceutical composition of a single tablet of inavogliflozin disclosed in the above-mentioned Republic of Korea Patent Application No. 10-2021-0130239 (Patent Document 1) is 75 mg. However, when the inavogliflozin part of the complex composition is composed of the composition of the single tablet, the total amount of the inavogliflozin part is less than about 1 / 13 of the total amount of the metformin part containing 1000 mg of metformin. Therefore, it is difficult to meet the ratio conditions between the first and second drugs required for a bilayer tablet press, and it is impossible to even attempt to manufacture a complex preparation with metformin into a bilayer tablet based on the composition of the single tablet of inavogliflozin.
[0015] The present invention relates to a composite composition for combination therapy of metformin and inavogliflozin.
[0016] In order to provide a combination composition of metformin and inavogliflozin that can solve the problems described above, a new formulation that takes into account the difference in content between the two drugs is required, and at the same time, such a combination composition must be able to achieve the same efficacy as the combination therapy of a single metformin tablet and a single inavogliflozin tablet, which is a reference drug.
[0017] The present inventors have conducted various studies to formulate a complex composition of metformin and inabogliflozin, and have confirmed that the above problems can be solved when the composition of the pharmaceutical composition is configured as follows.
[0018] Specifically, the present invention
[0019] A pharmaceutical composition in a single dosage form comprising a compartment containing inabogliflozin or a pharmaceutically acceptable salt thereof; and a compartment containing metformin or a pharmaceutically acceptable salt thereof, wherein the compartments are formulated in a form that is separated from each other.
[0020] The above-mentioned inabogliflozin compartment is included in an amount of 10 to 20 parts by weight per 100 parts by weight of the total pharmaceutical composition,
[0021] A pharmaceutical composition is provided wherein in the above inabogliflozin compartment, inabogliflozin or a pharmaceutically acceptable salt thereof is included in an amount of less than 0.3 parts by weight based on 100 parts by weight of the total of the inabogliflozin compartment.
[0022] As described above, since the content of inavogliflozin in the formulation is very low, it is difficult to implement it as a single matrix formulation when forming a complex composition with metformin, and therefore, a single dosage form pharmaceutical composition formulated in a form in which a compartment containing inavogliflozin or a pharmaceutically acceptable salt thereof (hereinafter also referred to as the 'inavogliflozin compartment' or the 'inavogliflozin part') and a compartment containing metformin or a pharmaceutically acceptable salt thereof (hereinafter also referred to as the 'metformin compartment' or the 'metformin part') are separated from each other is preferable.
[0023] Inavogliflozin used as an active ingredient in the present invention can be synthesized through known prior literature. In the present invention, inavogliflozin can be crystalline or amorphous. For example, inavogliflozin can be inavogliflozin crystalline form A, crystalline form B, crystalline form C, crystalline form D, crystalline form E or inavogliflozin amorphous, which are reported to have the following X-ray diffraction spectra through Korean Patent Publication No. 2017-0142904 or Korean Patent Application No. 2022-0123673.
[0024] Crystalline Form A: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ values selected from 6.2°±0.2°, 7.2°±0.2°, 8.8°±0.2°, 17.6°±0.2°, 19.0°±0.2°, 22.5°±0.2°, and 25.1°±0.2°
[0025] Crystalline Form B: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ values selected from 7.0°±0.2°, 14.9°±0.2°, 17.7°±0.2°, 18.8°±0.2°, 20.6°±0.2°, 21.8°±0.2°, and 23.5°±0.2°
[0026] Crystalline Form C: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ values selected from 5.6°±0.2°, 7.3°±0.2°, 15.7°±0.2°, 17.2°±0.2°, 18.9°±0.2°, 21.2°±0.2°, and 21.9°±0.2°
[0027] Crystalline Form D: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ values selected from 5.5°±0.2°, 7.2°±0.2°, 15.3°±0.2°, 17.2°±0.2°, 17.6°±0.2°, 18.9°±0.2°, and 21.1°±0.2°
[0028] Crystalline Form E: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ values selected from 4.93°±0.2°, 6.12°±0.2°, 7.43°±0.2°, 8.89°±0.2°, 9.74°±0.2°, 14.79°±0.2°, 15.79°±0.2°, 16.11°±0.2°, 19.79°±0.2°, and 22.83°±0.2°
[0029] The above crystal forms A, B, C, D and E can be characterized by X-ray diffraction spectra each having four or more peaks, for example, four, five, six, seven, eight or more, at the above-mentioned 2[θ values.
[0030] In a specific embodiment of the present invention, the average particle size of inabogliflozin may be 15 um or less, preferably 10 um or less. If the average particle size of inabogliflozin exceeds 15 um, it may be difficult to achieve the desired dissolution rate.
[0031] In the present invention, the inabogliflozin compartment is included in an amount of 10 to 20 parts by weight based on 100 parts by weight of the total pharmaceutical composition. Typically, when preparing a composite formulation with separate compartments such as a bilayer tablet, the weight ratio of the first drug compartment to the second drug compartment is within 1:2 to 1:4. This is because if the total weight of the compartment containing the drug with a smaller content is too small, the problem of improper tablet formation occurs.
[0032] When the inavogliflozin compartment is included in an amount of 10 to 20 parts by weight per 100 parts by weight of the total pharmaceutical composition, the metformin compartment is included in an amount of 90 to 80 parts by weight per 100 parts by weight of the total pharmaceutical composition. Since the weight ratio of the inavogliflozin compartment to the metformin compartment is 10 to 20:90 to 80, this is different from the composition of a typical separate compartment preparation.
[0033] In addition, in the inavogliflozin compartment, inavogliflozin or a pharmaceutically acceptable salt thereof is contained in an amount of less than 0.3 parts by weight based on 100 parts by weight of the total inavogliflozin compartment. This is different from the composition of a single tablet of inavogliflozin containing only inavogliflozin or a pharmaceutically acceptable salt thereof as an active ingredient (see Patent Document 1, containing 0.3 mg of inavogliflozin in a total tablet capacity of 75 mg).
[0034] More specifically, in the pharmaceutical composition according to the present invention, the inavogliflozin compartment comprises inavogliflozin or a pharmaceutically acceptable salt thereof, an excipient, a disintegrant, and a lubricant, and the metformin compartment comprises metformin or a pharmaceutically acceptable salt thereof, a binder, a release-promoting agent, and a lubricant.
[0035] In one embodiment, the inabogliflozin compartment comprises excipients selected from the group consisting of lactose monohydrate; mannitol; a mixture of microcrystalline cellulose and lactose monohydrate; and a mixture of microcrystalline cellulose, mannitol, and pregelatinized starch.
[0036] The following examples demonstrate changes in the dissolution rate of inavogliflozin depending on the selection of excipients. In the examples below, it was shown that the excipients used in the inavogliflozin compartment, including lactose monohydrate alone; mannitol alone; a mixture of microcrystalline cellulose and lactose monohydrate; or a mixture of microcrystalline cellulose, mannitol, and pregelatinized starch, provided equivalent dissolution rates of inavogliflozin compared to the single tablet of inavogliflozin.
[0037] The above excipients are not limited thereto, but are included in an amount of 80 to 85 parts by weight based on a total of 100 parts by weight of the inabogliflozin compartment.
[0038] In one specific embodiment of the present invention, when the inabogliflozin compartment includes lactose hydrate as an excipient, the lactose hydrate may be included in an amount of 40 to 100 parts by weight out of 100 parts by weight of the total excipients in the inabogliflozin compartment. When lactose hydrate is used as a sole excipient, it accounts for 100 parts by weight of the total excipients, and when lactose hydrate is used together with microcrystalline cellulose, it may be used in an amount of 40 parts by weight or more and less than 100 parts by weight out of 100 parts by weight of the total excipients.
[0039] In one specific embodiment of the present invention, when the inavogliflozin compartment includes mannitol as an excipient, mannitol may be included in an amount of 20 to 100 parts by weight out of 100 parts by weight of the total excipients in the inavogliflozin compartment. When mannitol is used as a sole excipient, it accounts for 100 parts by weight of the total excipients, and when mannitol is used together with microcrystalline cellulose and pregelatinized starch, it may be used in an amount of 20 parts by weight or more and less than 100 parts by weight out of 100 parts by weight of the total excipients.
[0040] In a specific example of the present invention, when the inabogliflozin compartment includes microcrystalline cellulose as an excipient, if the content of microcrystalline cellulose is too high, the dissolution of inabogliflozin is reduced, so it is not preferred to use it as a sole excipient, and it is preferred to use it as a mixture of microcrystalline cellulose and lactose monohydrate; or a mixture of microcrystalline cellulose, mannitol, and pregelatinized starch. Although not limited thereto, microcrystalline cellulose may be included in an amount of less than 65 parts by weight out of a total of 100 parts by weight of all excipients in the inabogliflozin compartment.
[0041] In a specific example of the present invention, when the inabogliflozin compartment includes pregelatinized starch as an excipient, the pregelatinized starch may be included in an amount of 5 to 40 parts by weight out of a total of 100 parts by weight of the excipients in the inabogliflozin compartment.
[0042] In another specific example, when the inabogliflozin compartment includes microcrystalline cellulose, mannitol, and pregelatinized starch as excipients, mannitol may be included in an amount of 20 to 65 parts by weight out of a total of 100 parts by weight of all excipients in the inabogliflozin compartment.
[0043] In another specific example, when the inavogliflozin compartment includes microcrystalline cellulose, mannitol, and pregelatinized starch as excipients, the microcrystalline cellulose, mannitol, and pregelatinized starch in the inavogliflozin compartment may be included in a weight ratio of 1:1 to 1.5:0.15 to 1.5. According to the present invention, it has been found that when the content of microcrystalline cellulose in the inavogliflozin compartment is high, it tends to be less soluble in water than other components, thereby hindering the release of inavogliflozin and reducing the dissolution rate. Mannitol and pregelatinized starch can improve the dissolution rate of inavogliflozin by complementing the shortcomings of microcrystalline cellulose.
[0044] In one specific example of the present invention, the inavogliflozin compartment may include a disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate, crospovidone, and low-substituted hydroxypropyl cellulose, and the disintegrant may be included in an amount of 5 to 20 parts by weight based on a total of 100 parts by weight of the inavogliflozin compartment. According to the following examples, when the content of the disintegrant in the inavogliflozin compartment is 25 parts by weight or more, it was confirmed that the dissolution profile is undesirable in terms of bioavailability, as it does not exhibit a dissolution rate of 80% or more within 10 minutes and a final dissolution rate of 85% or more. This is because excessive use of the disintegrant rather slows down the disintegration time and reduces the dissolution rate.
[0045] In one specific example of the present invention, the inabogliflozin compartment includes at least one of light anhydrous silicic acid and talc as a lubricant, and the lubricant may be included in an amount of 1.5 to 3 parts by weight based on a total of 100 parts by weight of the inabogliflozin compartment.
[0046] Meanwhile, in one specific example of the present invention, the metformin compartment comprises sodium carboxymethylcellulose, povidone or a mixture thereof as a binder, and the binder may be included in an amount of 2 to 5 parts by weight based on 100 parts by weight of the total metformin compartment.
[0047] In another specific embodiment, the metformin compartment comprises at least one of hydroxypropylmethylcellulose and polyethylene oxide as a release-promoting agent, and the release-promoting agent may be included in an amount of 15 to 40 parts by weight based on 100 parts by weight of the total of the metformin compartment.
[0048] Hydroxypropyl methylcellulose may preferably have an average viscosity of 100,000 mPa·s (75,000 to 140,000 mPa·s) to an average viscosity of 200,000 mPa·s (150,000 to 280,000 mPa·s) in a 2% w / w solution, and polyethylene oxide may preferably have an average molecular weight of 2,000,000 to 5,000,000. When the viscosity of hydroxypropyl cellulose and the molecular weight of polyethylene oxide are low, the formation of a polymer matrix for sustained release is incomplete, which may affect the release rate of the drug.
[0049] In one specific example of the present invention, the metformin compartment may contain 0.5 to 1 part by weight of magnesium stearate as a lubricant based on 100 parts by weight of the total metformin compartment.
[0050] As disclosed in Patent Document 1, the inabogliflozin compartment has a Tmax of 1 to 2 hours due to the drug's characteristics, and it is desirable to formulate it as an immediate-release formulation to achieve appropriate Cmax and AUC.
[0051] Preferably, in the pharmaceutical composition according to the present invention, the dissolution rate of the inavogliflozin or a pharmaceutically acceptable salt thereof in a pH 1.2 dissolution medium after 10 minutes is 75% or more, preferably 80% or more, of the total content of the inavogliflozin or a pharmaceutically acceptable salt thereof.
[0052] Preferably, in the pharmaceutical composition according to the present invention, the dissolution rate of the inavogliflozin or a pharmaceutically acceptable salt thereof in a pH 1.2 dissolution medium after 45 minutes is 80% or more, preferably 85% or more, of the total content of the inavogliflozin or a pharmaceutically acceptable salt thereof.
[0053] The dissolution rate of the active ingredient in the pharmaceutical composition is the maximum blood concentration (C) when the drug is administered. max) and the area under the blood concentration-time curve (AUC), so conversely, it is important to adjust the dissolution rate of the pharmaceutical composition to achieve appropriate Cmax and AUC. Since inavogliflozin has a Tmax of 1 to 2 hours, the drug absorption rate from above is considered important. The above dissolution rate was measured under the condition of dissolution volume 1.2 by the dissolution test method 2 (paddle method) of the Korean Pharmacopoeia. Specific conditions can be referred to the experimental example below.
[0054] It is desirable to formulate the metformin compartment as a sustained-release formulation because rapid drug release when formulated as a regular tablet may cause excessive blood sugar lowering and gastrointestinal upset.
[0055] Preferably, in the pharmaceutical composition according to the present invention, the dissolution rate of the metformin or its pharmaceutically acceptable salt in the pH 6.8 dissolution medium after 1 hour is 15 to 35%, preferably 20% or more, of the total content of metformin or its pharmaceutically acceptable salt.
[0056] Preferably, in the pharmaceutical composition according to the present invention, the dissolution rate of the metformin or its pharmaceutically acceptable salt in the pH 6.8 dissolution medium after 3 hours is 40 to 60%, preferably 45% or more, of the total content of metformin or its pharmaceutically acceptable salt.
[0057] Preferably, in the pharmaceutical composition according to the present invention, the dissolution rate of the metformin or its pharmaceutically acceptable salt in a pH 6.8 dissolution medium after 12 hours is 80% or more, preferably 85% or more, of the total content of metformin or its pharmaceutically acceptable salt.
[0058] Since metformin has a Tmax of approximately 4 hours before a meal and approximately 6 hours after a meal, drug absorption in the intestines is considered important. The above dissolution rate was measured under conditions of a pH of 6.8 in the dissolution solution using the first dissolution test method (rotary sample container method) of the Korean Pharmacopoeia. Specific conditions can be found in the experimental examples below.
[0059] The pharmaceutical composition according to the present invention may further comprise pharmaceutically acceptable additives in addition to the ingredients presented above. Examples of other additives include lubricants, colorants, and the like.
[0060] The above-mentioned lubricants include stearic acid, stearic acid salts (e.g., magnesium stearate), light anhydrous silicic acid, talc, corn starch, carnauba wax, magnesium silicate, synthetic aluminum silicate, hydrogenated oil, white lead, titanium dioxide, microcrystalline cellulose, macrogol 4000 and 6000, isopropyl myristate, calcium hydrogen phosphate, and mixtures thereof.
[0061] In one specific embodiment of the present invention, the inabogliflozin compartment comprises a granule in which a pre-mixed granule and a post-mixed portion containing inabogliflozin or a pharmaceutically acceptable salt thereof are mixed.
[0062] During the research process for the formulation of inabogliflozin, the inventors of the present invention confirmed that manufacturing granules and formulating them into tablets, etc., is advantageous in terms of drug content uniformity and formulation uniformity.
[0063] The granules in the Inabogliflozin compartment are manufactured by mixing pre-mixed granules and post-mixed granules.
[0064] The above premixed granules may include inabogliflozin or a pharmaceutically acceptable salt thereof, excipients, and a lubricant. In addition, the postmixed portion may include excipients, a disintegrant, and a lubricant.
[0065] Descriptions of excipients, disintegrants, and lubricants in the Inabogliflozin compartment are the same as those described above, so they are omitted to avoid duplicate description.
[0066] In a specific embodiment of the present invention, the pre-mixed granules and post-mixed portion within the inabogliflozin compartment may each include one or more excipients.
[0067] In one embodiment of the present invention, the premixed granules in the inabogliflozin compartment may include microcrystalline cellulose, and the postmixed portion may include mannitol and pregelatinized starch.
[0068] The weight ratio of the excipients in the premixed granules and the excipients in the postmixed portion within the inabogliflozin compartment may be 1:1 to 1:4.
[0069] As the proportion of microcrystalline cellulose in the premixed granules within the inabogliflozin compartment increases, the dissolution rate may decrease, so it was determined that it is desirable to maintain the weight ratio within an appropriate range.
[0070] Although not limited thereto, the granules in the inavogliflozin compartment of the pharmaceutical composition of the present invention may be dry granules. Dry granulation enables the formation of granules having a suitable particle size distribution, thereby minimizing weight variation between individual tablets due to excellent flowability and compression moldability during the tableting process. Dry granules play an important role in producing a bilayer tablet having a uniform inavogliflozin content. In another specific embodiment, the granules may be wet granules.
[0071] In one specific embodiment of the present invention, the metformin compartment comprises a granule mixture of premixed granules and postmixed granules containing metformin or a pharmaceutically acceptable salt thereof.
[0072] In the case of the metformin compartment, the content of the main ingredient, metformin, is very high and the physical properties are poor, so it is desirable to manufacture it in the form of wet or dry granules to avoid various problems in the manufacturing process, such as poor tableting and poor coating.
[0073] Although not limited thereto, the granules within the metformin compartment may be wet granules. Alternatively, they may be dry granules.
[0074] The granules in the metformin compartment are prepared by mixing pre-mixed granules and post-mixed granules.
[0075] The premixed granules may contain metformin or a pharmaceutically acceptable salt thereof and a binder. In addition, the postmixed portion may contain a sustained-release agent and a lubricant.
[0076] Descriptions of binders, extenders, and lubricants within the metformin compartment are the same as those described above, so they are omitted to avoid redundant description.
[0077] Meanwhile, in the present invention, the pharmaceutical composition may be in a dosage form for oral administration, such as a tablet. In one specific embodiment of the present invention, the pharmaceutical composition may be in the form of a tablet. In a preferred embodiment, the pharmaceutical composition may be in the form of a bilayer tablet.
[0078] In one specific embodiment of the present invention, the pharmaceutical composition may contain inabogliflozin in a dosage of 0.1 to 0.5 mg, preferably 0.15 mg or 0.3 mg.
[0079] In a preferred embodiment, the pharmaceutical composition may comprise metformin in a dosage of 500 mg to 1000 mg. Preferably, the pharmaceutical composition may comprise metformin in a dosage of 500 mg, 750 mg, or 1000 mg.
[0080] The pharmaceutical composition according to the present invention may be administered orally once a day, but is not limited thereto.
[0081] The pharmaceutical composition according to the present invention enables the realization of an excellent formulation that provides a level of efficacy equivalent to that of a combination therapy of a single metformin tablet and a single inavogliflozin tablet, despite a large difference in the contents of metformin and inavogliflozin.
[0082] Figure 1 is a graph comparing the dissolution rates of inabogliflozin in the formulations of Examples 1 to 4, Comparative Examples 1 and 2 with those of a control drug under pH 1.2 conditions.
[0083] Figure 2 is a graph comparing the dissolution rates of inabogliflozin in the formulations of Examples 1, 5 to 6, and Comparative Example 3 with those of a control drug under pH 1.2 conditions.
[0084] Figure 3 is a graph comparing the dissolution rates of inabogliflozin of the formulations of Examples 1, 7 to 10, and Comparative Example 4 with those of a control drug under pH 1.2 conditions.
[0085] Figure 4 is a graph comparing the dissolution rates of metformin hydrochloride of the formulations of Example 1 and Examples 11 to 17 with those of a control drug under pH 1.2 conditions.
[0086] Hereinafter, preferred examples are presented to aid understanding of the present invention. However, the following examples are merely illustrative of the present invention and are not intended to limit the scope of the present invention. Furthermore, while preferred methods and samples are described herein, similar or equivalent methods are also included within the scope of the present invention.
[0087]
[0088] [Example]
[0089] Example 1
[0090] Step 1: Preparation of granules containing inabogliflozin
[0091] Granules containing inavogliflozin were prepared according to the composition of the inavogliflozin part in Table 1 below. Inavogliflozin was mixed with microcrystalline cellulose, light anhydrous silicic acid, and talc, and dry granulation was used to prepare a plate-shaped compressed product, which was then pulverized using a Comil to prepare a dry granule. Then, mannitol, pregelatinized starch, croscarmellose sodium, talc, and a pigment blend were added to the dry granule and mixed to prepare inavogliflozin granules.
[0092] Step 2: Preparation of granules containing metformin hydrochloride
[0093] Granules containing metformin hydrochloride were prepared according to the metformin composition of Table 1 below. Metformin hydrochloride and sodium carboxymethylcellulose were mixed, kneaded with water as a binder, and dried. The dried material was ground to prepare wet granules, and then hydroxypropyl methylcellulose (average viscosity 100,000 mPa·s) and magnesium stearate were added and mixed to prepare metformin hydrochloride granules.
[0094] Step 3: Preparation of the complex tablet
[0095] A bilayer tablet was manufactured by compressing metformin hydrochloride granules as the first layer and inavogliflozin granules as the second layer using a bilayer tablet press, thereby manufacturing a bilayer combination tablet containing 1000 mg of metformin hydrochloride and 0.3 mg of inavogliflozin.
[0096] Ingredient Example 1 Inavogliflozin Buinavogliflozin 0.3 Microcrystalline cellulose 55.0 Mannitol 70.0 Pregelatinized starch 40.0 Croscarmellose sodium 30.0 Light anhydrous silicic acid 2.0 Talc 2.5 Pigment blend orange 0.2 Metformin hydrochloride Bumetformin hydrochloride 1000.0 Carboxymethylcellulose sodium 50.0 Hydroxypropylmethylcellulose 300.0 Magnesium stearate 10.0
[0097]
[0098] Comparative examples 1-2
[0099] Step 1: Preparation of granules containing inabogliflozin
[0100] Granules containing inabogliflozin were manufactured according to the composition of the inabogliflozin part in Table 2 below.
[0101] Microcrystalline cellulose, light anhydrous silicic acid, and talc were mixed with inabogliflozin, and a plate-shaped compressed material was prepared using dry granulation, which was then pulverized using a comille to prepare a dry granule, and croscarmellose sodium, talc, and a pigment blend were mixed to prepare inabogliflozin granules of Comparative Example 1.
[0102] Inabogliflozin was mixed with pregelatinized starch, light anhydrous silicic acid, and talc, and a plate-shaped compressed material was manufactured using dry granulation, which was then pulverized using a comille to manufacture a dry granule, and pregelatinized starch, croscarmellose sodium, talc, and a pigment blend were mixed to manufacture the inabogliflozin granules of Comparative Example 2.
[0103] Step 2: Preparation of granules containing metformin hydrochloride
[0104] Granules containing metformin hydrochloride were prepared according to the metformin composition in Table 2 below. Metformin hydrochloride and sodium carboxymethylcellulose were mixed, kneaded with water as a binder, and dried. The dried material was ground to prepare wet granules, and then hydroxypropyl methylcellulose (average viscosity 100,000 mPa·s) and magnesium stearate were added and mixed to prepare metformin hydrochloride granules.
[0105] Step 3: Preparation of the complex tablet
[0106] In the same manner as in Example 1, a bilayer tablet was formed using a bilayer tablet press, with metformin hydrochloride granules as the first layer and inavogliflozin granules as the second layer, to manufacture a bilayer composite tablet containing 1000 mg of metformin hydrochloride and 0.3 mg of inavogliflozin.
[0107] Ingredient Comparison Example 1 Comparison Example 2 Inavogliflozin Buinavogliflozin 0.3 0.3 Microcrystalline cellulose 165.0 Pregelatinized starch 165.0 Croscarmellose sodium 30.0 30.0 Light anhydrous silicic acid 2.0 2.0 Talc 2.5 2.5 Pigment blend orange 0.2 0.2 Metformin hydrochloride Bumetformin hydrochloride 1000.0 1000.0 Carboxymethylcellulose sodium 50.0 50.0 Hydroxypropylmethylcellulose 300.0 300.0 Magnesium stearate 10.0 10.0
[0108]
[0109] Examples 2-4
[0110] Step 1: Preparation of granules containing inabogliflozin
[0111] Granules containing inabogliflozin were manufactured according to the composition of the inabogliflozin part in Table 3 below.
[0112] Inabogliflozin was mixed with microcrystalline cellulose, lactose monohydrate, light anhydrous silicic acid, and talc, and a plate-shaped compressed material was prepared using dry granulation. The dry granules were then pulverized using a Comil to prepare dry granules. Croscarmellose sodium, talc, and a pigment blend were mixed to prepare the inabogliflozin granules of Example 2.
[0113] Inabogliflozin was mixed with lactose monohydrate, light anhydrous silicic acid, and talc, and a plate-shaped compressed product was prepared using dry granulation. The dry granules were then pulverized using a Comil to prepare dry granules. Croscarmellose sodium, talc, and a pigment blend were mixed to prepare the inabogliflozin granules of Example 3.
[0114] Mannitol, light anhydrous silicic acid, and talc were mixed with inabogliflozin, and a plate-shaped compressed material was prepared using dry granulation, and the dry granulation material was prepared by crushing using a comille, and mannitol, croscarmellose sodium, talc, and pigment blend were mixed to prepare the inabogliflozin granules of Example 3.
[0115] Step 2: Preparation of granules containing metformin hydrochloride
[0116] Granules containing metformin hydrochloride were prepared according to the composition of the metformin portion in Table 3 below. Metformin hydrochloride and sodium carboxymethylcellulose were mixed, kneaded with water as a binder, and dried. The dried material was ground to prepare wet granules, and then hydroxypropyl methylcellulose (average viscosity 100,000 mPa·s) and magnesium stearate were added and mixed to prepare metformin hydrochloride granules.
[0117] Step 3: Preparation of the complex tablet
[0118] In the same manner as in Example 1, a bilayer tablet was formed using a bilayer tablet press, with metformin hydrochloride granules as the first layer and inavogliflozin granules as the second layer, to manufacture a bilayer composite tablet containing 1000 mg of metformin hydrochloride and 0.3 mg of inavogliflozin.
[0119] Ingredients Example 2 Example 3 Example 4 Inavogliflozin Buinavogliflozin 0.30.30.3 Microcrystalline cellulose 82.5 Lactose monohydrate 82.5 165.0 Mannitol 165.0 Croscarmellose sodium 30 30.0 30.0 Light anhydrous silicic acid 22.0 2.0 Talc 2.5 2.5 2.5 Pigment blend orange 0.20.20.2 Metformin hydrochloride Bumetformin hydrochloride 1000.0 1000.0 1000.0 Carboxymethylcellulose sodium 50.0 50.0 50.0 Hydroxypropylmethylcellulose 300.0 300.0 300.0 Magnesium stearate 10.0 10.0 10.0
[0120]
[0121] Comparative Example 3
[0122] Step 1: Preparation of granules containing inabogliflozin
[0123] Granules containing inabogliflozin were manufactured according to the composition of the inabogliflozin part in Table 4 below.
[0124] Microcrystalline cellulose, light anhydrous silicic acid, and talc were mixed with inabogliflozin, and a plate-shaped compressed material was manufactured using dry granulation, and the dry granulation material was manufactured by crushing using a comille, and mannitol, pregelatinized starch, croscarmellose sodium, talc, and pigment blend were mixed to manufacture inabogliflozin granules of Comparative Example 3.
[0125] Step 2: Preparation of granules containing metformin hydrochloride
[0126] Granules containing metformin hydrochloride were manufactured according to the composition of the metformin portion in Table 4 below.
[0127] Metformin hydrochloride and carboxymethylcellulose sodium were mixed, kneaded with water as a binder, and dried. The dried material was ground to produce wet granules, then hydroxypropyl methylcellulose (average viscosity 100,000 mPa·s) and magnesium stearate were added and mixed to produce metformin hydrochloride granules.
[0128] Step 3: Preparation of the complex tablet
[0129] In the same manner as in Example 1, a bilayer tablet was formed using a bilayer tablet press, with metformin hydrochloride granules as the first layer and inavogliflozin granules as the second layer, to manufacture a bilayer composite tablet containing 1000 mg of metformin hydrochloride and 0.3 mg of inavogliflozin.
[0130] Ingredient comparison example 3 Inavogliflozin Buinavogliflozin 0.3 Microcrystalline cellulose 55 Mannitol 10 Pregelatinized starch 100 Croscarmellose sodium 30 Light anhydrous silicic acid 2 Talc 2.5 Pigment blend orange 0.2 Metformin hydrochloride Bumetformin hydrochloride 1000.0 Carboxymethylcellulose sodium 50.0 Hydroxypropylmethylcellulose 300.0 Magnesium stearate 10.0
[0131]
[0132] Examples 5-6
[0133] Step 1: Preparation of granules containing inabogliflozin
[0134] Granules containing inabogliflozin were manufactured according to the composition of the inabogliflozin part in Table 5 below.
[0135] Inabogliflozin was mixed with microcrystalline cellulose, light anhydrous silicic acid, and talc, and a plate-shaped compressed material was prepared using dry granulation, and the dry granulation material was prepared by pulverizing using a Comil, and mannitol, pregelatinized starch, croscarmellose sodium, talc, and pigment blend were mixed to prepare the inabogliflozin granules of Examples 5 and 6.
[0136] Step 2: Preparation of granules containing metformin hydrochloride
[0137] Granules containing metformin hydrochloride were manufactured according to the composition of the metformin portion in Table 5 below.
[0138] Metformin hydrochloride and carboxymethylcellulose sodium were mixed, kneaded with water as a binder, and dried. The dried material was ground to produce wet granules, and then hydroxypropyl methylcellulose (average viscosity 100,000 mPa·s) and magnesium stearate were added and mixed to produce metformin hydrochloride granules.
[0139] Step 3: Preparation of the complex tablet
[0140] In the same manner as in Example 1, a bilayer tablet was formed using a bilayer tablet press, with metformin hydrochloride granules as the first layer and inavogliflozin granules as the second layer, to manufacture a bilayer composite tablet containing 1000 mg of metformin hydrochloride and 0.3 mg of inavogliflozin.
[0141] Ingredients Example 5 Example 6 Inavogliflozin Buinavogliflozin 0.30.3 Microcrystalline cellulose 55.0 55.0 Mannitol 100.0 40.0 Pregelatinized starch 10.0 70.0 Croscarmellose sodium 30.0 30.0 Light anhydrous silicic acid 2.0 2.0 Talc 2.5 2.5 Pigment blend orange 0.2 0.2 Metformin hydrochloride Bumetformin hydrochloride 1000.0 1000.0 Carboxymethylcellulose sodium 50.0 50.0 Hydroxypropylmethylcellulose 300.0 300.0 Magnesium stearate 10.0 10.0
[0142]
[0143] Comparative Example 4
[0144] Step 1: Preparation of granules containing inabogliflozin
[0145] Granules containing inabogliflozin were manufactured according to the composition of the inabogliflozin part in Table 6 below.
[0146] Microcrystalline cellulose, light anhydrous silicic acid, and talc were mixed with inabogliflozin, and a plate-shaped compressed material was manufactured using dry granulation, which was then pulverized using a comille to manufacture a dry granule, and mannitol, pregelatinized starch, croscarmellose sodium, talc, and a pigment blend were mixed to manufacture inabogliflozin granules of Comparative Example 4.
[0147] Step 2: Preparation of granules containing metformin hydrochloride
[0148] Granules containing metformin hydrochloride were manufactured according to the composition of the metformin portion in Table 6 below.
[0149] Metformin hydrochloride and carboxymethylcellulose sodium were mixed, kneaded with water as a binder, and dried. The dried material was ground to produce wet granules, then hydroxypropyl methylcellulose (average viscosity 100,000 mPa·s) and magnesium stearate were added and mixed to produce metformin hydrochloride granules.
[0150] Step 3: Preparation of the complex tablet
[0151] In the same manner as in Example 1, a bilayer tablet was formed using a bilayer tablet press, with metformin hydrochloride granules as the first layer and inavogliflozin granules as the second layer, to manufacture a bilayer composite tablet containing 1000 mg of metformin hydrochloride and 0.3 mg of inavogliflozin.
[0152] Ingredient comparison example 4 Inabogliflozin Buinabogliflozin 0.3 Microcrystalline cellulose 55 Mannitol 70 Pregelatinized starch 40 Croscarmellose sodium 50 Light anhydrous silicic acid 2.0 Talc 2.5 Pigment blend orange 0.2 Metformin hydrochloride Bumetformin hydrochloride 1000.0 Carboxymethylcellulose sodium 50.0 Hydroxypropylmethylcellulose 300.0 Magnesium stearate 10.0
[0153]
[0154] Examples 7-10
[0155] Step 1: Preparation of granules containing inabogliflozin
[0156] Granules containing inabogliflozin were manufactured according to the composition of the inabogliflozin part in Table 7 below.
[0157] Inabogliflozin was mixed with microcrystalline cellulose, light anhydrous silicic acid, and talc, and a plate-shaped compressed material was prepared using dry granulation, which was then pulverized using a Comil to prepare a dry granule, and mannitol, pregelatinized starch, croscarmellose sodium, talc, and a pigment blend were mixed to prepare the inabogliflozin granules of Example 7.
[0158] Inabogliflozin granules of Example 8 were prepared by mixing mannitol, pregelatinized starch, sodium starch glycolate, talc, and pigment blend into the above dry granules.
[0159] Inabogliflozin granules of Example 9 were prepared by mixing mannitol, pregelatinized starch, crospovidone, talc, and pigment blend into the above dry granules.
[0160] Mannitol, pregelatinized starch, and low-substituted hydroxypropyl cellulose were mixed with the above dry granules to prepare the inabogliflozin granules of Example 10.
[0161] Step 2: Preparation of granules containing metformin hydrochloride
[0162] Granules containing metformin hydrochloride were manufactured according to the composition of the metformin portion in Table 7 below.
[0163] Metformin hydrochloride and carboxymethylcellulose sodium were mixed, kneaded with water as a binder, and dried. The dried material was ground to produce wet granules, then hydroxypropyl methylcellulose (average viscosity 100,000 mPa·s) and magnesium stearate were added and mixed to produce metformin hydrochloride granules.
[0164] Step 3: Preparation of the complex tablet
[0165] In the same manner as in Example 1, a bilayer tablet was formed using a bilayer tablet press, with metformin hydrochloride granules as the first layer and inavogliflozin granules as the second layer, to manufacture a bilayer composite tablet containing 1000 mg of metformin hydrochloride and 0.3 mg of inavogliflozin.
[0166] Ingredients Example 7 Example 8 Example 9 Example 10 Inavogliflozin Buinavogliflozin 0.30.30.30.3 Microcrystalline cellulose 55.0 55.0 55.0 55.0 Mannitol 70.0 70.0 70.0 70.0 Pregelatinized starch 40.0 40.0 40.0 40.0 Croscarmellose sodium 10.0 --- Sodium starch glycolate - 30.0 --- Crospovidone - 30.0 --- Low-substituted hydroxypropyl cellulose - 30.0 Light anhydrous silicic acid 2.0 2.0 2.0 2.0 Talc 2.5 2.5 2.5 2.5 Pigment blend Orange 0.20.20.20.2 Metformin Hydrochloride Butemetformin Hydrochloride 1000.01000.01000.01000.0 Sodium Carboxymethylcellulose 50.050.050.050.0 Hydroxypropylmethylcellulose 300.0300.0300.0300.0 Magnesium Stearate 10.010.010.010.0
[0167]
[0168] Examples 11-14
[0169] Step 1: Preparation of granules containing inabogliflozin
[0170] Granules containing inabogliflozin were manufactured according to the composition of the inabogliflozin part in Table 8 below.
[0171] Inabogliflozin was mixed with microcrystalline cellulose, light anhydrous silicic acid, and talc, and a plate-shaped compressed material was manufactured using dry granulation. The dry granulation material was manufactured by crushing using a Comil, and mannitol, pregelatinized starch, croscarmellose sodium, talc, and pigment blend were added and mixed to manufacture Inabogliflozin granules.
[0172] Step 2: Preparation of granules containing metformin hydrochloride
[0173] Granules containing metformin hydrochloride were manufactured according to the composition of the metformin portion in Table 8 below.
[0174] Metformin hydrochloride and povidone were mixed, combined with water as a binder, and dried. The dried material was ground to produce wet granules, and then hydroxypropyl methylcellulose (average viscosity 100,000 mPa·s) and magnesium stearate were added and mixed to produce metformin hydrochloride granules of Example 11.
[0175] Hydroxypropyl methylcellulose (average viscosity 200,000 mPa·s) and magnesium stearate were added to the above wet granules and mixed to prepare metformin hydrochloride granules of Example 12.
[0176] Polyethylene oxide (average molecular weight 2,000,000) and magnesium stearate were added to the above wet granules and mixed to prepare metformin hydrochloride granules of Example 13.
[0177] Polyethylene oxide (average molecular weight 5,000,000) and magnesium stearate were added to the above wet granules and mixed to prepare metformin hydrochloride granules of Example 14.
[0178] Step 3: Preparation of the complex tablet
[0179] In the same manner as in Example 1, a bilayer tablet was formed using a bilayer tablet press, with metformin hydrochloride granules as the first layer and inavogliflozin granules as the second layer, to manufacture a bilayer composite tablet containing 1000 mg of metformin hydrochloride and 0.3 mg of inavogliflozin.
[0180] Ingredients Example 11 Example 12 Example 13 Example 14 Inavogliflozin Buinavogliflozin 0.30.30.30.3 Microcrystalline cellulose 55.0 55.0 55.0 55.0 Mannitol 70.0 70.0 70.0 70.0 Pregelatinized starch 40.0 40.0 40.0 40.0 Croscarmellose sodium 30.0 30.0 30.0 30.0 Light anhydrous silicic acid 2.0 2.0 2.0 2.0 Talc 2.5 2.5 2.5 2.5 Pigment blend Orange 0.20.20.20.2 Metformin hydrochloride Bumetformin hydrochloride 1000.0 1000.0 1000.0 1000.0 Povidone 50.0 50.0 50.0 50.0 Hydroxypropyl methylcellulose (average viscosity 100,000 mPa s) 300.0 --- Hydroxypropyl methylcellulose (average viscosity 200,000 mPa s) - 300.0 --- Polyethylene oxide (average molecular weight 2,000,000) - 300.0 --- Polyethylene oxide (average molecular weight 5,000,000) - 300.0 Magnesium stearate 10.0 10.0 10.0 10.0
[0181]
[0182] Examples 15-17
[0183] Step 1: Preparation of granules containing inabogliflozin
[0184] Granules containing inabogliflozin were manufactured according to the composition of the inabogliflozin part in Table 9 below.
[0185] Inabogliflozin was mixed with microcrystalline cellulose, light anhydrous silicic acid, and talc, and a plate-shaped compressed material was manufactured using dry granulation. The dry granulation material was manufactured by crushing using a Comil, and mannitol, pregelatinized starch, croscarmellose sodium, talc, and pigment blend were added and mixed to manufacture Inabogliflozin granules.
[0186] Step 2: Preparation of granules containing metformin hydrochloride
[0187] Granules containing metformin hydrochloride were prepared according to the composition of the metformin portion in Table 9 below. Metformin hydrochloride and sodium carboxymethylcellulose were mixed, kneaded with water as a binder, and dried. The dried material was ground to prepare wet granules, and then hydroxypropyl methylcellulose (average viscosity 200,000 mPa·s) and magnesium stearate were added and mixed to prepare metformin hydrochloride granules of Example 15.
[0188] Polyethylene oxide (average molecular weight 2,000,000) and magnesium stearate were added to the above wet granules and mixed to prepare metformin hydrochloride granules of Example 16.
[0189] Polyethylene oxide (average molecular weight 5,000,000) and magnesium stearate were added to the above wet granules and mixed to prepare metformin hydrochloride granules of Example 17.
[0190] Step 3: Preparation of the complex tablet
[0191] In the same manner as in Example 1, a bilayer tablet was formed using a bilayer tablet press, with metformin hydrochloride granules as the first layer and inavogliflozin granules as the second layer, to manufacture a bilayer composite tablet containing 1000 mg of metformin hydrochloride and 0.3 mg of inavogliflozin.
[0192] Ingredients Example 15 Example 16 Example 17 Inavogliflozin Buinavogliflozin 0.30.30.3 Microcrystalline cellulose 55.0 55.0 55.0 Mannitol 70.0 70.0 70.0 Pregelatinized starch 40.0 40.0 40.0 Croscarmellose sodium 30.0 30.0 30.0 Light anhydrous silicic acid 2.0 2.0 2.0 Talc 2.5 2.5 2.5 Pigment blend orange 0.20.20.2 Metformin hydrochloride Bumetformin hydrochloride 1000.0 1000.0 1000.0 Carboxymethylcellulose sodium 50.0 50.0 50.0 Hydroxypropylmethylcellulose (average viscosity 200,000 mPa s) 300.0--Polyethylene oxide (average molecular weight 2,000,000)-300.0-Polyethylene oxide (average molecular weight 5,000,000)--300.0Magnesium stearate 10.010.010.0
[0193]
[0194] Experimental Example 1: Hardness Test
[0195] A hardness test physically measures the hardness of an oral dosage form (unit: kP). The test involved placing tablets on a hardness measuring device and measuring their hardness. The tablets manufactured in each of the examples and comparative examples were tested. The tableting pressure applied to the tablets was set to 25–28 kN, and the tablet hardness measurement results are shown in Table 10 below.
[0196] Hardness (kP) Example 1 Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 22.4 23.3 20.2 20.2 19.6 Example 2 Example 3 Example 4 Example 5 Example 6 22.0 17.7 17.2 21.7 19.4 Example 7 Example 8 Example 9 Example 10 Example 1 11.9 8 18.5 21.2 21.4 38.0 Example 12 Example 13 Example 14 Example 15 Example 16 42.6 36.0 23.3 28.0 31.0 Example 17 29.9
[0197] As a result of the hardness test, all manufactured tablets showed a hardness of 15 kP or higher, confirming that there were no problems in tablet manufacturing.
[0198]
[0199] Experimental Example 2: Disintegration Test
[0200] Disintegration tests were performed on the inabogliflozin layers of Comparative Examples 1 to 4 and Examples 1 to 10 according to the disintegration test method in the General Test Methods of the Korean Pharmacopoeia. The results are shown in Table 11 below.
[0201] Disintegration time Example 1 Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 55 seconds 1 minute 48 seconds 3 minutes 3 seconds 2 minutes 12 seconds 1 minute 50 seconds Example 2 Example 3 Example 4 Example 5 Example 6 1 minute 1 minute 40 seconds 1 minute 23 seconds 55 seconds 1 minute 28 seconds Example 7 Example 8 Example 9 Example 10 45 seconds 55 seconds 40 seconds 47 seconds
[0202] The disintegration test is a test method to check whether tablets, capsules, granules, pills, and suppositories disintegrate (disappear or disperse into a particle size below a specified level) in a test solution under specified conditions within a specified time period. It does not check whether the active ingredient of the formulation is completely dissolved, but it can predict the degree of dissolution in the solvent to some extent. The disintegration test results confirmed that the comparative examples disintegrated relatively slowly compared to the examples.
[0203]
[0204] Experimental Example 3: Stability Evaluation
[0205] The formulation of Example 1 was sealed in an HDPE (High Density PolyEthylene) bottle and stored under long-term test conditions (25°C, 60%RH), and the contents of inavogliflozin and metformin and the amounts of related substances were measured by liquid chromatography analysis at 3, 6, 9, and 12 months. After storage under accelerated test conditions (40°C, 75RH), the contents of inavogliflozin and metformin and the amounts of related substances were measured by liquid chromatography analysis at 1, 3, and 6 months. The results are shown in Tables 12 and 13 below.
[0206] Long-term test results (unit: %) Initial 3 months 6 months 9 months 12 months Content Navogliflozin 99.9 10.5 102.5 99.6 102.1 Metformin 98.3 98.9 98.7 100.0 97.5 Related substances Navogliflozin Other related substances 0.04 0.18 0.11 0.10 0.16 Total related substances 0.13 0.23 0.23 0.22 0.26 Metformin Cyanoguanidine N.DN.DN.DN.DN.D Total related substances N.DN.DN.DN.DN.DN DMA (Standard: 48 ppb or less) N / AN.D 0.83 ppb 6.29 ppb 5.15 ppb
[0207] Accelerated test results (unit: %) Initial 1 month 3 months 6 months Content Navogliflozin 99.9 100.7 99.9 101.3 Metformin 98.3 100.1 99.4 98.4 Related substances Navogliflozin Other related substances 0.04 0.05 0.17 0.21 Total related substances 0.13 0.12 0.25 0.51 Metformin Cyanoguanidine N.DN.DN.DN.D Total related substances N.DN.DN.DN.DN DMA (Standard: 48 ppb or less) N / AN / A 10.57 ppb 10.10 ppb
[0208] As shown in Tables 12 and 13 above, stability was confirmed under long-term, accelerated testing conditions for 12 months through stability tests using the contents and flexible substances of Example 1. In addition, it was confirmed that the amount of NDMA (N-nitrosodimethylamine), a suspected carcinogen, generated was below the maximum allowable daily amount (48 nanograms, 0.048 ppb), which is the provisional management standard, when taking up to 2,000 mg per day.
[0209]
[0210] Experimental Example 4: Dissolution Test
[0211] According to the dissolution test method of the Korean Pharmacopoeia, the dissolution test of inavogliflozin and metformin manufactured in Comparative Examples 1 to 4 and Examples 1 to 17 was performed under the same conditions as those described in Tables 14 and 15 below. In order to compare the dissolution rate with the combination tablet of the present invention, “Enblo Tablet” of Daewoong Pharmaceutical, a single agent of inavogliflozin, and “Glucophage XL sustained-release tablet 1000 mg” of Merck, a single agent of metformin, were tested under the same conditions as the combination tablet of the present invention.
[0212] Inabogliflozin dissolution test conditions Item Conditions Dissolution test device Agilent 708-DS Dissolution test method Method 2 (paddle method) Dissolution solution pH 1.2 Dissolution solution temperature 37.0℃ Dissolution solution amount 500 mL Rotation speed 50 rpm Analysis method - Detector: UV spectrophotometer (measurement wavelength: 218 nm) - Mobile phase: phosphate hydrogen buffer: acetonitrile = 55:45 (v / v)
[0213]
[0214] Dissolution test conditions for metformin Item Conditions Dissolution test device Agilent 708-DS Dissolution test method Method 1 (rotating sample container method) Dissolution solution pH 6.8 Dissolution solution temperature 37.0℃ Dissolution solution amount 900 mL Rotation speed 100 rpm Analysis method - Detector: UV spectrophotometer (measurement wavelength: 218 nm) - Mobile phase: phosphate hydrogen buffer: acetonitrile = 85:15 (v / v)
[0215] The results of the dissolution test of Inabogliflozin are shown in Tables 16-18 and Figures 1-3.
[0216] Dissolution rate of Inabogliflozin according to filler type Time (h) 0 5 1 0 1 5 3 0 4 5 Control 0 79.99 1 9 2.89 4 9 4 Comparative Example 1 0 57.36 4.66 7.47 2.87 6.9 Comparative Example 2 0 26 6 4 7 2.17 6.27 8.4 Example 1 0 77.78 7.78 9.99 2.79 3.8 Example 2 0 70 79.88 3.4 8.19 0.1 Example 3 0 62.38 0 84.28 7.88 9.4 Example 4 0 79.98 8.28 9.89 1 9 1.1
[0217]
[0218] Dissolution rate of Inabogliflozin according to filler ratio Time (h) 0 5 1 0 1 5 3 0 4 5 Control 0 7 9 1 9 2 8 9 4 9 4 Comparative Example 3 0 4 0 8 6 6 7 3 7 7 6 7 7 7 Example 1 0 7 7 8 7 7 8 9 2 7 9 3 8 Example 5 0 8 0 8 5 3 8 9 1 6 9 3 2 Example 6 0 7 4 8 6 5 8 8 1 9 0 2 9 1 2
[0219]
[0220] Dissolution rate of inabogliflozin according to the type of disintegrant Time (h) 0 5 1 0 1 5 3 0 4 5 Control 0 7 9 1 9 2 8 9 4 9 4 Comparative Example 4 6 9 6 8 7 7 8 1 8 3 1 Example 1 7 7 7 8 7 8 9 2 7 9 3 8 Example 7 0 8 1 5 8 6 7 8 7 6 9 0 3 9 1 6 Example 8 0 7 3 7 8 3 4 8 3 5 8 5 8 6 8 Example 9 0 8 8 1 8 8 3 8 9 4 9 0 5 9 1 7 Example 10 0 8 5 7 9 1 2 9 0 6 9 2 7 9 3 8
[0221] Since Inabogliflozin is a component with a Tmax of approximately 1 hour, its dissolution in gastric juice is expected to have a significant impact on its bioavailability. Therefore, the dissolution rate at pH 1.2 is considered important, and Comparative Examples 1 to 4, which did not show a dissolution rate of 80% or more within 10 minutes and a final dissolution rate of 85% or more, were considered undesirable from a bioavailability perspective.
[0222]
[0223] The results of the dissolution test of metformin are shown in Table 19 and Figure 4.
[0224] Time (h) 00.250.511.5235681012f2 Counter-Treaty 010.316.926.834.340.752.268.674.784.590.895.0-Example 108.815.024.632.038.549.165.070.979.886.589.772.66Example 1108.214.724.432.038.249.164.971.280.886.590.573.67Example 1208.314.924.732.639.651.067.773.584.090.793.988.56Example 1308.014.123.731.638.349.568.974.284.189.491.480.16 Example 1406.510.818.726.531.741.658.465.077.084.087.454.34 Example 1508.915.726.034.341.453.069.476.186.292.695.891.13 Example 1608.013.823.531.938.951.870.979.088.492.896.074.90 Example 1708.514.223.431.037.748.565.372.983.190.895.178.29
[0225] The dissolution rate of metformin was confirmed to be equivalent in all examples as specified in the pharmaceutical equivalence test standards: i) the difference in the average dissolution rate between the reference drug and the test drug at all dissolution rate comparison points was within 15%, and ii) the similarity factor (f2) was 50 or higher at all dissolution rate measurement points.
[0226]
[0227] Experimental Example 5: Clinical Trial
[0228] A pharmacodynamic test (PK test) was performed on the pharmaceutical composition of Example 1 to evaluate bioequivalence with the reference drug.
[0229] According to the bioequivalence test of the Pharmaceutical Equivalence Test Standards of the Pharmaceutical Affairs Law Collection, if both items in the 90% confidence interval of the log-transformed mean difference between the reference drug and the test drug are within log 0.8 to log 1.25, the pharmaceutical equivalence test is considered equivalent.
[0230] The pharmaceutical composition of Example 1 was selected as a test drug, and a clinical trial was conducted to compare the blood concentrations of each drug using the combined administration of Daewoong Pharmaceutical's "Enblo Tablet," a single drug of inabogliflozin, and Merck's "Glucophage XL Extended-Range Tablet 1000 mg," a single drug of metformin, as a control group.
[0231] The clinical trial was a randomized, two-group, four-period (before and after meals) crossover study. Blood samples were drawn at appropriate times after dosing. Plasma concentrations of inavogliflozin and metformin were measured, and pharmacokinetic parameters (AUC and Cmax) were calculated and evaluated.
[0232]
[0233] Before meal administration or vogliflozinPK parametersGMR RatioCI_90%_LowerCI_90%_UpperResultsCmax0.990990.28108.76 EquivalentAUC1.025993.1373113.00 EquivalentMetforminPK parametersRatioCI_90%_LowerCI_90%_UpperResultsCmax0.997983.81118.81 EquivalentAUC0.957681.41112.64 Equivalent
[0234] Postprandial administration or vogliflozinPK parametersRatioCI_90%_LowerCI_90%_UpperResultsCmax0.87590.820.93EquivalentAUC1.03470.981.09EquivalentMetforminPK parametersRatioCI_90%_LowerCI_90%_UpperResultsCmax1.01470.981.05EquivalentAUC1.00380.971.04Equivalent
[0235] As a result of the test, it was confirmed that the pharmaceutical composition of Example 1 showed bioequivalence with the control drug when administered together both before and after a meal.
Claims
1. A pharmaceutical composition in a single dosage form comprising a compartment containing metformin or a pharmaceutically acceptable salt thereof; and a compartment containing inavogliflozin or a pharmaceutically acceptable salt thereof, wherein the compartments are formulated in a form that is separated from each other. The above-mentioned inabogliflozin compartment is included in an amount of 10 to 20 parts by weight per 100 parts by weight of the total pharmaceutical composition, A pharmaceutical composition wherein in the above inabogliflozin compartment, inabogliflozin or a pharmaceutically acceptable salt thereof is contained in an amount of less than 0.3 parts by weight based on 100 parts by weight of the total of the inabogliflozin compartment.
2. In paragraph 1, The above inabogliflozin compartment comprises inabogliflozin or a pharmaceutically acceptable salt thereof, excipients, disintegrants and lubricants, A pharmaceutical composition wherein the metformin compartment comprises metformin or a pharmaceutically acceptable salt thereof, a binder, a release-promoting agent and a lubricant.
3. In paragraph 1, A pharmaceutical composition wherein the inabogliflozin compartment comprises an excipient selected from the group consisting of lactose monohydrate; mannitol; a mixture of microcrystalline cellulose and lactose monohydrate; and a mixture of microcrystalline cellulose, mannitol, and pregelatinized starch, wherein the excipient is included in an amount of 80 to 85 parts by weight based on 100 parts by weight of the total of the inabogliflozin compartment.
4. In paragraph 1, A pharmaceutical composition wherein, when the above inabogliflozin compartment includes lactose hydrate as an excipient, the lactose hydrate is included in an amount of 40 to 100 parts by weight out of a total of 100 parts by weight of all excipients in the above inabogliflozin compartment.
5. In paragraph 1, A pharmaceutical composition wherein, when the above inabogliflozin compartment includes mannitol as an excipient, mannitol is included in an amount of 20 to 100 parts by weight out of a total of 100 parts by weight of all excipients in the above inabogliflozin compartment.
6. In paragraph 1, A pharmaceutical composition wherein, when the above inabogliflozin compartment includes microcrystalline cellulose as an excipient, the microcrystalline cellulose is included in less than 65 parts by weight out of 100 parts by weight of the total excipients in the above inabogliflozin compartment.
7. In paragraph 1, A pharmaceutical composition wherein, when the above-mentioned inabogliflozin compartment includes pregelatinized starch as an excipient, the pregelatinized starch is included in an amount of 5 to 40 parts by weight out of a total of 100 parts by weight of all excipients in the above-mentioned inabogliflozin compartment.
8. In paragraph 1, A pharmaceutical composition wherein, when the above inabogliflozin compartment includes microcrystalline cellulose, mannitol, and pregelatinized starch as excipients, mannitol is included in an amount of 20 to 65 parts by weight out of a total of 100 parts by weight of all excipients in the above inabogliflozin compartment.
9. In paragraph 1, A pharmaceutical composition wherein, when the inabogliflozin compartment includes microcrystalline cellulose, mannitol, and pregelatinized starch as excipients, the microcrystalline cellulose, mannitol, and pregelatinized starch in the inabogliflozin compartment are included in a weight ratio of 1:0.5 to 2:0.15 to 1.
5.
10. In paragraph 1, A pharmaceutical composition wherein the inabogliflozin compartment comprises a disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate, crospovidone, and low-substituted hydroxypropyl cellulose, and the disintegrant is included in an amount of 5 to 20 parts by weight based on a total of 100 parts by weight of the inabogliflozin compartment.
11. In paragraph 1, A pharmaceutical composition wherein the inabogliflozin compartment comprises at least one of light anhydrous silicic acid and talc as a lubricant, and the lubricant is contained in an amount of 1.5 to 3 parts by weight based on 100 parts by weight of the total of the inabogliflozin compartment.
12. In paragraph 1, A pharmaceutical composition wherein the metformin compartment comprises sodium carboxymethylcellulose, povidone or a mixture thereof as a binder, and the binder is contained in an amount of 2 to 5 parts by weight based on 100 parts by weight of the total of the metformin compartment.
13. In paragraph 1, A pharmaceutical composition wherein the metformin compartment comprises at least one of hydroxypropyl methylcellulose and polyethylene oxide as a release-promoting agent, and the release-promoting agent is contained in an amount of 15 to 40 parts by weight based on 100 parts by weight of the total of the metformin compartment.
14. In paragraph 1, A pharmaceutical composition wherein the metformin compartment contains magnesium stearate as a lubricant in an amount of 0.5 to 1 part by weight based on 100 parts by weight of the total metformin compartment.
15. In paragraph 1, A pharmaceutical composition wherein the dissolution rate of the above inabogliflozin or a pharmaceutically acceptable salt thereof in a pH 1.2 dissolution medium after 10 minutes is 80% or more of the total content of the inabogliflozin or a pharmaceutically acceptable salt thereof.
16. In paragraph 1, A pharmaceutical composition wherein the dissolution rate of the above inabogliflozin or a pharmaceutically acceptable salt thereof in a pH 1.2 dissolution medium after 45 minutes is 85% or more of the total content of the inabogliflozin or a pharmaceutically acceptable salt thereof.
17. In paragraph 1, A pharmaceutical composition having a dissolution rate of metformin or a pharmaceutically acceptable salt thereof in a pH 6.8 dissolution medium after 1 hour of at least 20% of the total content of metformin or a pharmaceutically acceptable salt thereof.
18. In paragraph 1, A pharmaceutical composition having a dissolution rate of metformin or a pharmaceutically acceptable salt thereof in a pH 6.8 dissolution medium after 3 hours of at least 45% of the total content of metformin or a pharmaceutically acceptable salt thereof.
19. In paragraph 1, A pharmaceutical composition having a dissolution rate of metformin or a pharmaceutically acceptable salt thereof in a pH 6.8 dissolution medium after 12 hours of at least 85% of the total content of metformin or a pharmaceutically acceptable salt thereof.
20. In paragraph 1, A pharmaceutical composition wherein the above inabogliflozin compartment comprises a granule mixture of premixed granules and a postmixed portion containing inabogliflozin or a pharmaceutically acceptable salt thereof.
21. In paragraph 20, A pharmaceutical composition wherein the above premixed granules comprise inabogliflozin or a pharmaceutically acceptable salt thereof, an excipient, and a lubricant.
22. In paragraph 20, A pharmaceutical composition wherein the above-mentioned post-mixing part comprises an excipient, a disintegrant, and a lubricant.
23. In paragraph 20, A pharmaceutical composition wherein the pre-mixed granules and post-mixed portion each contain one or more excipients.
24. In paragraph 20, A pharmaceutical composition wherein the weight ratio of the excipients in the premixed granules and the excipients in the postmixed portion is 1:1 to 1:
4.
25. In paragraph 20, The above granules are a pharmaceutical composition that is a dry granule.
26. In paragraph 1, A pharmaceutical composition wherein the metformin compartment comprises a granule mixture of premixed granules and postmixed granules containing metformin or a pharmaceutically acceptable salt thereof.
27. In paragraph 26, A pharmaceutical composition wherein the above granules are wet granules.
28. In paragraph 1, The above pharmaceutical composition has a tablet formulation.
29. In paragraph 1, The above pharmaceutical composition has a two-layer tablet formulation.
30. In paragraph 1, The above pharmaceutical composition comprises inabogliflozin in a dosage of 0.1 mg to 0.5 mg.
31. In paragraph 1, The pharmaceutical composition above comprises metformin in a dosage of 500 mg to 1000 mg.
